Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Myriad Genetics (NASDAQ: MYGN) has announced a collaboration with Gabbi, a telehealth provider specializing in breast cancer risk assessment. The partnership will integrate Gabbi's telehealth risk assessment program and specialist care services with Myriad's MyRisk® with RiskScore® Hereditary Cancer Test.
Through this collaboration, Gabbi's platform will provide logistics and educational support for breast cancer risk assessment, connecting high-risk patients with clinicians for evaluation using the MyRisk test. The test's precision science enables 53% of patients to qualify for medical management changes, such as increased frequency of mammograms or MRI imaging.
Myriad Genetics (NASDAQ: MYGN) ha annunciato una collaborazione con Gabbi, un fornitore di telemedicina specializzato nella valutazione del rischio di cancro al seno. La partnership integrerà il programma di valutazione del rischio di telemedicina di Gabbi e i servizi di assistenza specialistica con il MyRisk® con RiskScore® Test per il Cancro Ereditario di Myriad.
Grazie a questa collaborazione, la piattaforma di Gabbi fornirà supporto logistico ed educativo per la valutazione del rischio di cancro al seno, collegando i pazienti ad alto rischio con i clinici per la valutazione utilizzando il test MyRisk. La scienza di precisione del test consente a 53% dei pazienti di qualificarsi per modifiche nella gestione medica, come un aumento della frequenza delle mammografie o delle immagini MRI.
Myriad Genetics (NASDAQ: MYGN) ha anunciado una colaboración con Gabbi, un proveedor de telemedicina especializado en la evaluación del riesgo de cáncer de mama. La asociación integrará el programa de evaluación de riesgo de telemedicina de Gabbi y los servicios de atención especializada con el MyRisk® con RiskScore® Prueba de Cáncer Hereditario de Myriad.
A través de esta colaboración, la plataforma de Gabbi proporcionará apoyo logístico y educativo para la evaluación del riesgo de cáncer de mama, conectando a pacientes de alto riesgo con clínicos para la evaluación utilizando la prueba MyRisk. La ciencia de precisión de la prueba permite que el 53% de los pacientes califiquen para cambios en la gestión médica, como un aumento en la frecuencia de mamografías o imágenes por MRI.
Myriad Genetics (NASDAQ: MYGN)는 유방암 위험 평가를 전문으로 하는 원격 의료 제공업체인 Gabbi와 협력한다고 발표했습니다. 이 파트너십은 Gabbi의 원격 의료 위험 평가 프로그램과 전문 진료 서비스를 Myriad의 MyRisk®와 RiskScore® 유전성 암 검사와 통합할 것입니다.
이 협력을 통해 Gabbi의 플랫폼은 유방암 위험 평가를 위한 물류 및 교육 지원을 제공하며, 고위험 환자와 임상 의사를 연결하여 MyRisk 검사를 통해 평가를 진행합니다. 이 검사의 정밀 과학은 환자의 53%가 의료 관리 변경 자격을 갖추도록 합니다. 예를 들어, 유방 촬영술 또는 MRI 촬영의 빈도를 증가시키는 것입니다.
Myriad Genetics (NASDAQ: MYGN) a annoncé une collaboration avec Gabbi, un fournisseur de télémédecine spécialisé dans l'évaluation du risque de cancer du sein. Ce partenariat intégrera le programme d'évaluation des risques de télémédecine de Gabbi et les services de soins spécialisés avec le MyRisk® avec RiskScore® Test de Cancer Héréditaire de Myriad.
Grâce à cette collaboration, la plateforme de Gabbi fournira un soutien logistique et éducatif pour l'évaluation du risque de cancer du sein, reliant les patients à haut risque à des cliniciens pour une évaluation utilisant le test MyRisk. La science de précision du test permet à 53% des patients de se qualifier pour des changements dans la gestion médicale, tels qu'une fréquence accrue des mammographies ou des examens IRM.
Myriad Genetics (NASDAQ: MYGN) hat eine Zusammenarbeit mit Gabbi angekündigt, einem Telemedizinanbieter, der auf die Risikobewertung von Brustkrebs spezialisiert ist. Die Partnerschaft wird das Telemedizin-Risikobewertungsprogramm und die spezialisierten Dienstleistungen von Gabbi mit dem MyRisk® mit RiskScore® Erblichen Krebs-Test von Myriad integrieren.
Durch diese Zusammenarbeit wird die Plattform von Gabbi logistische und bildungsbezogene Unterstützung für die Risikobewertung von Brustkrebs bieten und hochriskante Patienten mit Kliniken für die Bewertung unter Verwendung des MyRisk-Tests verbinden. Die präzise Wissenschaft des Tests ermöglicht es, dass 53% der Patienten für Änderungen im medizinischen Management qualifiziert werden, wie z.B. eine erhöhte Häufigkeit von Mammographien oder MRT-Untersuchungen.
- Strategic partnership expands access to genetic testing services
- Integration with telehealth platform enhances service delivery
- 53% of patients qualify for medical management changes through testing
- None.
SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk® with RiskScore® Hereditary Cancer Test.
“After losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicating late-stage breast cancer by helping women understand their risk and access the care they need,” said Kaitlin Christine, Founder and CEO, Gabbi. “Genetic testing is a crucial aspect of assessing a woman’s risk and highly informs her care. The gold-standard MyRisk with RiskScore Hereditary Cancer Test delivers clear, actionable results, which can become the foundation for a personalized care plan.”
Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated for the MyRisk Hereditary Cancer Test, ensuring a seamless experience.
The precision science behind MyRisk with RiskScore enables
“Hereditary cancer risk assessment may provide peace of mind and help inform access to early detection screening tools for women at an elevated risk for cancer,” said Melissa Gonzales, President, Myriad Women’s Health. “We fully support Gabbi’s mission to empower women to better understand their risk of breast cancer and make informed health decisions, as it aligns with our own mission as well.”
About Gabbi
Gabbi empowers thousands of women to understand and reduce their risks of breast cancer. Gabbi’s clinicians are available on the same day to answer patient questions, help them understand their risk, and develop a plan to manage and reduce cancer risks including ordering and prescribing necessary imaging and testing. Once a woman knows her risk, Gabbi – supported by its team of clinical breast specialists – equips her with a personalized action plan and real-time care navigation. This ensures the woman receives the care she needs when she needs it and gets to an early detection. For more information, visit www.gabbi.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to hereditary cancer risk assessment and how it may provide peace of mind and help inform access to early detection screening tools for women at an elevated risk for cancer. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
_________________________
1 Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
2 American Cancer Society. “Breast Cancer Risk Factors You Cannot Change.”
FAQ
What is the impact of Myriad Genetics (MYGN) partnership with Gabbi on breast cancer screening?
How effective is MYGN's MyRisk with RiskScore Hereditary Cancer Test?
What services will Gabbi provide in the MYGN collaboration?
What are the key benefits of the MYGN-Gabbi partnership for patients?
